Mirati Therapeutics, Inc. Common Stock

MRTX

Market cap $4.12B

Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?